Loading...
XNAS
GNPX
Market cap5mUSD
Dec 05, Last price  
3.36USD
1D
0.30%
1Q
1,364.05%
IPO
-98.13%
Name

Genprex Inc

Chart & Performance

D1W1MN
XNAS:GNPX chart
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
58.48%
Rev. gr., 5y
%
Revenues
0k
Net income
-21.39b
L+69,206.42%
-1,069,722-4,132,159-3,314,157-12,372,339-10,654,768-17,923,959-19,590,491-29,463,105-30,860,461-21,388,282,000
CFO
-17m
L-30.68%
-688,261-1,248,263-2,171,594-6,846,534-6,918,721-13,935,086-14,284,924-17,778,964-24,738,603-17,149,088

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.
URL
https://www.genprex.com/
IPO date
Mar 29, 2018
Employees
30
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT